• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

眼部的药物相互作用。用于炎性角膜炎的皮质类固醇与抗生素联合治疗。

Drug interaction in the eye. Concurrent corticosteroid-antibiotic therapy for inflammatory keratitis.

作者信息

Leibowitz H M, Kupferman A

出版信息

Arch Ophthalmol. 1977 Apr;95(4):682-5. doi: 10.1001/archopht.1977.04450040148023.

DOI:10.1001/archopht.1977.04450040148023
PMID:192185
Abstract

Concurrent instillation of individual preparations of a corticosteroid and an antibiotic resulted in significantly (P less than .05) lower peak corneal and aqueous humor steroid levels than those achieved by the steroid alone. Both the interval elapsing between instillation of the two drugs and the sequence in which they were administered influenced subsequent steroid bioavailability. Corticosteroid levels in the cornea after administration of a combination steroid-antibiotic preparation were not significantly different (P less than .05) from those detected after instillation of the same steroid alone, suggesting that, for the treatment of corneal disorders, use of a combination preparation may offer a method to circumvent certain drug interactions. The decrease in ocular steroid bioavailability could not be directly equated with differences in antinflammatory effectiveness, so that the therapeutic relevance of the demonstrated drug interaction is not known.

摘要

同时滴注皮质类固醇和抗生素的单独制剂,导致角膜和房水类固醇峰值水平显著低于单独使用类固醇时的水平(P<0.05)。两种药物滴注之间的时间间隔以及给药顺序都会影响随后的类固醇生物利用度。联合使用类固醇-抗生素制剂给药后角膜中的皮质类固醇水平与单独滴注相同类固醇后检测到的水平无显著差异(P<0.05),这表明,对于角膜疾病的治疗,使用联合制剂可能提供一种规避某些药物相互作用的方法。眼内类固醇生物利用度的降低不能直接等同于抗炎效果的差异,因此所证明的药物相互作用的治疗相关性尚不清楚。

相似文献

1
Drug interaction in the eye. Concurrent corticosteroid-antibiotic therapy for inflammatory keratitis.眼部的药物相互作用。用于炎性角膜炎的皮质类固醇与抗生素联合治疗。
Arch Ophthalmol. 1977 Apr;95(4):682-5. doi: 10.1001/archopht.1977.04450040148023.
2
Topically administered corticosteroids: effect on antibiotic-treated bacterial keratitis.局部应用皮质类固醇:对抗生素治疗细菌性角膜炎的影响。
Arch Ophthalmol. 1980 Jul;98(7):1287-90. doi: 10.1001/archopht.1980.01020040139024.
3
Management of inflammation in the cornea and conjunctiva.角膜和结膜炎症的管理。
Ophthalmology. 1980 Aug;87(8):753-8. doi: 10.1016/s0161-6420(80)35174-9.
4
Quantitation of bacterial infection and antibiotic effect in the cornea.
Arch Ophthalmol. 1976 Nov;94(11):1981-4. doi: 10.1001/archopht.1976.03910040687017.
5
Antiinflammatory medications.抗炎药物。
Int Ophthalmol Clin. 1980 Fall;20(3):117-34. doi: 10.1097/00004397-198002030-00012.
6
Human conjunctivitis. II. Treatment.人类结膜炎。II. 治疗。
Arch Ophthalmol. 1976 Oct;94(10):1752-6. doi: 10.1001/archopht.1976.03910040526011.
7
The effectiveness of an improved combination therapy for experimental Staphylococcus aureus keratitis.改良联合疗法治疗实验性金黄色葡萄球菌角膜炎的疗效。
Adv Ther. 2010 Dec;27(12):933-40. doi: 10.1007/s12325-010-0082-x. Epub 2010 Oct 22.
8
Corticosteroid-Antibiotic Interactions in Bacteria that Cause Corneal Infection.引起角膜感染的细菌中的皮质类固醇-抗生素相互作用。
Transl Vis Sci Technol. 2023 May 1;12(5):16. doi: 10.1167/tvst.12.5.16.
9
Shigella keratitis: a case report.志贺氏菌性角膜炎:病例报告
J Pediatr. 1969 Feb;74(2):294-6. doi: 10.1016/s0022-3476(69)80079-x.
10
Topical antibiotic therapy of Pseudomonas aeruginosa keratitis.铜绿假单胞菌性角膜炎的局部抗生素治疗
Arch Ophthalmol. 1979 Sep;97(9):1699-1702. doi: 10.1001/archopht.1979.01020020267016.

引用本文的文献

1
Progress in Ocular Drug Delivery: Challenges and Constraints.眼部药物递送的进展:挑战与限制
Handb Exp Pharmacol. 2024;284:267-288. doi: 10.1007/164_2023_693.
2
Corticosteroid-Antibiotic Interactions in Bacteria that Cause Corneal Infection.引起角膜感染的细菌中的皮质类固醇-抗生素相互作用。
Transl Vis Sci Technol. 2023 May 1;12(5):16. doi: 10.1167/tvst.12.5.16.
3
Formulation Considerations for the Management of Dry Eye Disease.干眼症管理的制剂考量
Pharmaceutics. 2021 Feb 3;13(2):207. doi: 10.3390/pharmaceutics13020207.
4
The effects of oral and topical corticosteroid in rabbit corneas.口服和局部用皮质类固醇对兔角膜的影响。
BMC Ophthalmol. 2016 Sep 5;16(1):160. doi: 10.1186/s12886-016-0339-5.
5
Intraocular penetration of sequentially instilled topical moxifloxacin, gatifloxacin, and levofloxacin.依次滴用的局部用莫西沙星、加替沙星和左氧氟沙星的眼内穿透性。
Clin Ophthalmol. 2009;3:553-7. doi: 10.2147/opth.s7757. Epub 2009 Oct 19.
6
Prophylactic effectiveness of tobramycin-dexamethasone eye drops compared with tobramycin/vehicle eye drops in controlling post-surgical inflammation in cataract patients : prospective, randomised, double-masked, two-arm, parallel-group, placebo-controlled, multicentre study.比较托百士地塞米松滴眼液与托百士/载体滴眼液控制白内障患者术后炎症的预防效果:前瞻性、随机、双盲、双臂、平行组、安慰剂对照、多中心研究。
Clin Drug Investig. 2004;24(9):523-33. doi: 10.2165/00044011-200424090-00003.
7
Locally administered ocular corticosteroids: benefits and risks.局部应用的眼部皮质类固醇:益处与风险。
Drug Saf. 2002;25(1):33-55. doi: 10.2165/00002018-200225010-00004.
8
Pharmacokinetics of ophthalmic corticosteroids.眼科皮质类固醇的药代动力学。
Br J Ophthalmol. 1992 Nov;76(11):681-4. doi: 10.1136/bjo.76.11.681.